MAR 25, 2015 6:27 AM PDT

Thomson Reuters Names Most Promising Drugs of 2015

WRITTEN BY: Ilene Schneider
The Thomson Reuters annual forecast found a significant increase in the number of blockbusters set to enter this year's market. The Intellectual Property and Science Business of Thomson Reuters Annual Forecast found a significant increase in the number of blockbusters set to enter this year's market.

The study revealed a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach over $3 billion in sales by 2019. Thomson Reuters analysts utilized Cortellis™ Competitive Intelligence, its source for drug pipeline, deals, patents, and company content, to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $ 1 billion+) by 2019.

At the beginning of 2014, Thomson Reuters Cortellis Competitive Intelligence named three drugs expected to enter the market that year and achieve sales of over $1 billion within five years. All are still forecast to be $1 billion-plus blockbusters, according to the 2015 report. They are Gilead Sciences' oral drug Sovaldi (sofosbuvir) for hepatitis C virus (HCV) infection, GlaxoSmithKline/Theravance's Anoro Ellipta (umeclidinium plus vilanterol) for chronic obstructive pulmonary disease (COPD) and Gilead was Zydelig (idelalisib) for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphomas such as follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL).

In its 2015 report Thomson Reuters predicts that three drugs will exceed $3 billion in sales by 2019: Bristol-Myers Squibb's (BMS) melanoma drug Opdivo (nivolumab); Regeneron Pharmaceuticals and Sanofi's Praluent (alirocumab) for hypercholesterolemia and Novartis' LCZ-696 (sacubitril and valsartan) for chronic heart failure. Thomson Reuters also predicts other "blockbuster" drug entrants: Pfizer's Ibrance (palbociclib) for breast cancer; Vertex Pharmaceutical's lumacaftor plus ivacaftor for cystic fibrosis; AbbVie's Viekira Pak (veruprevir, ritonavir, ombitasvir and dasabuvir) for HCV; Amgen and Astellas Pharma's evolocumab for hypercholesterolemia/hyperlipidemia; Merck & Co.'s Gardasil 9 vaccine against human papillomavirus (HPV) infection; Otsuka Pharmaceutical and Lundbeck's brexpiprazole for schizophrenia and depression; Sanofi's Toujeo (new-formulation insulin glargine) for diabetes; and Novartis' Cosentyx (secukinumab) for psoriasis and psoriatic arthritis.

The report goes on to say, "Key trends to watch in 2015 are the rise of immuno-oncology approaches for treating cancer, the race to be the next big cholesterol drug, the entry of a first-in-class heart failure drug, and the entry of more convenient all-oral regimes for HCV. Opdivo versus Keytruda is the race to watch in the immuno-oncology space, while Praluent and evolocumab battle it out in the cholesterol field, LCZ-696 aims to make its mark for heart failure, and Gilead, AbbVie and Merck compete to win space in the HCV market." It concludes that far more blockbusters will enter the market this year than in 2014.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
APR 16, 2020
Health & Medicine
Structural Basis of Receptor Recognition by SARS-CoV-2
APR 16, 2020
Structural Basis of Receptor Recognition by SARS-CoV-2
As mortality and infection rates rise globally, it appears that SARS-CoV-2, the virus responsible for the COVID-19 pande ...
MAY 23, 2020
Microbiology
The FDA Yanks Some COVID-19 Antibody Tests From the Market
MAY 23, 2020
The FDA Yanks Some COVID-19 Antibody Tests From the Market
The massive demand for diagnostic testing led the FDA to open a short window for many testing products to go to market w ...
JUL 08, 2020
Health & Medicine
The Myths About CBD and Coronavirus
JUL 08, 2020
The Myths About CBD and Coronavirus
Research collected over the last 20 years suggests that cannabidiol – the primary cannabinoid in CBD oil – h ...
JUL 07, 2020
Coronavirus
No Evidence Showing Asthma Increases Severity of COVID-19
JUL 07, 2020
No Evidence Showing Asthma Increases Severity of COVID-19
Scientists have been scrambling to learn as much as possible about the novel coronavirus, which causes the disease COVID ...
JUL 15, 2020
Immunology
Immune Memory to Thwart Recurring Cancer
JUL 15, 2020
Immune Memory to Thwart Recurring Cancer
Preventing cancer from returning in the body is an integral part of any anti-cancer treatment plan. New discoveries from ...
AUG 05, 2020
Coronavirus
Age-old Immune Components Affecting COVID-19 Severity
AUG 05, 2020
Age-old Immune Components Affecting COVID-19 Severity
One of the most unsettling aspects of the coronavirus pandemic is the wide range of severity those affected seem to expe ...
Loading Comments...